Latest Rosiglitazone Stories
RECORD trial also demonstrates durable blood sugar control over time with Avandia LONDON, RESEARCH TRIANGLE PARK, N.C., and NEW ORLEANS, June 5 /PRNewswire/ -- Clinical trial results presented today at the American Diabetes Association annual meeting show that overall rates of cardiovascular hospitalization and cardiovascular death are similar in patients taking Avandia (rosiglitazone) compared to those receiving metformin and sulfonylurea. Results from the 4,447-patient Rosiglitazone...
Today's announcement hurts thousands of Avandia patients, counsel says HOUSTON, June 5 /PRNewswire/ -- Noted Houston trial lawyer Mark Lanier of The Lanier Law Firm says "useless trick science" is the basis for a new study being unveiled today in New Orleans by drug maker GlaxoSmithKline (NYSE: GSK) about the side effects caused by the company's diabetes medication Avandia, which reportedly has been linked to heart problems in thousands of patients. Mr. Lanier represents many former...
LOS ALTOS, Calif., May 28 /PRNewswire/ -- InteKrin Therapeutics, Inc. announced today it will present Phase 2a clinical data for INT131, a Selective PPAR Modulator (SPPARM), at the American Diabetes Association annual meeting in New Orleans Saturday, June 6, 2009 during the "Novel Diabetes Therapies in Development in Humans" session at 4:00 pm CDT. Dr. Alex DePaoli, Chief Medical Officer of InteKrin Therapeutics, will provide a summary of the latest clinical data supporting the design of...
- Welchol Added to Metformin Significantly Reduced A1C and LDL-C in Patients with Type 2 Diabetes - Open-Label Extension Study Demonstrated the Safety and Durability of Welchol for up to 78 Weeks of Treatment PARSIPPANY, N.J., May 15 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced today that data from a 16-week, randomized, open-label pilot study demonstrated that Welchol(R) (colesevelam HCl) significantly improved glycemic control and reduced mean LDL cholesterol (LDL-C) when added...
BETHESDA, Md., May 14 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that, on May 12, 2009, its Board of Directors elected a new, independent Director, Thomas B. Peter, to begin serving immediately. Mr. Peter will also serve on the Company's Compensation and Nominating Committees....
JACKSONVILLE, Fla., April 14 /PRNewswire-USNewswire/ -- When concerns were raised about the safety of the diabetes medication, rosiglitazone, in May 2007, many patients and their doctors made the decision to discontinue use of the drug. A study published today in Endocrine Practice by Dr. Etta Fanning from the University of Texas Health Science Center along with her colleagues reported that many patients who discontinued use of rosiglitazone received less therapy and higher blood glucose...
 Treatment with the glitazone class of diabetes drugs leads to a "modest" increase in the risk of diabetic macular edema (DME)"”a common complication that can lead to vision loss, reports a study in the April issue of the American Journal of Ophthalmology (http://www.elsevier.com/locate/ajo), published by Elsevier.Using a database of about 170,000 patients with diabetes, Drs. Donald S. Fong and Richard Contreras of Southern California Permanente Medical Group analyzed the link...
Federal health officials are examining a potentially ground breaking diabetes medication from Bristol-Myers Squibb because it appears free of heart-related side effects that have plagued similar treatments.The Food and Drug Administration will still ask an outside panel to scrutinize the company's safety data at a meeting Wednesday.Bristol-Myers and partner AstraZeneca want the FDA to approve Onglyza, which promises to decrease blood sugar levels in patients with type 2 diabetes.Type 2...
ST. PAUL, Minn., March 26 /PRNewswire/ -- Pharmacy benefit manager Prime Therapeutics (Prime) announced that three of its clinical pharmacists, Patrick Gleason, PharmD, FCCP, BCPS, Cathy Starner, PharmD and Jeremy Schafer, PharmD were awarded the Journal of Managed Care Pharmacy (JMCP) Award of Excellence for their manuscript assessing rosiglitazone and pioglitazone utilization trends and associated medical and pharmacy claims data indicating risk for an adverse cardiovascular event....
NEW YORK, Feb. 24 /PRNewswire/ -- Mindset BioPharmaceuticals (USA) Inc ("MINDSET") a company privately held by MPM Capital and other shareholders announced today that it has received a Notice of Allowance in Europe related to patent applications describing the use of insulin sensitizer drugs for the prevention and treatment of memory loss. Drugs of this type include Rosiglitazone and Pioglitazone which have been approved for the treatment of type II diabetes mellitus. Glucose is used by...
